The higher efficacy of treatment in these patients might be due to greater activation of the trigeminovascular system, where the CGRP plays a key role in mechanisms underlying migraine pain—a mediator of nociception, neuroinflammation, and vasodilation (6). The gene discussed is CALCA; the disease is migraine disorder.